Antonia Scott, Mulé James J, Weber Jeffrey S
H. Lee Moffitt Comprehensive Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, Florida 33612, USA.
Curr Opin Immunol. 2004 Apr;16(2):130-6. doi: 10.1016/j.coi.2004.01.012.
The clinical application of immunotherapy for cancer is rapidly moving forward in multiple areas, including the adoptive transfer of anti-tumor-reactive T cells and the use of 'therapeutic' vaccines. Recently, both clinical and immunological endpoints have shown improvement. Novel strategies designed in the laboratory and proven in preclinical animal tumor models are now entering the clinic, with the intent of enhancing current therapeutic efficacy. These novel strategies involve breaking tolerance to tumor self-antigens by inhibiting regulatory cells, boosting T-cell co-stimulation and using combinations of recombinant cytokines and other defined molecules with 'immuno-enhancing' activities.
癌症免疫疗法的临床应用正在多个领域迅速推进，包括抗肿瘤反应性T细胞的过继性转移以及“治疗性”疫苗的使用。最近，临床和免疫终点均已显示出改善。在实验室设计并在临床前动物肿瘤模型中得到验证的新策略目前正在进入临床，目的是提高当前的治疗效果。这些新策略包括通过抑制调节性细胞来打破对肿瘤自身抗原的耐受性、增强T细胞共刺激作用以及使用重组细胞因子和其他具有“免疫增强”活性的特定分子的组合。
